QualityStocks would like to highlight
Zenosense, Inc. (
OTCQB: ZENO). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
In the company’s news,
Zenosense has been working with a large university hospital in Madrid, Spain to test the effectiveness of its specially designed volatile organic compound (VOC) detection techniques. The collaboration is particularly promising, because, in addition to its work with Zenosense, the university hospital has been directly involved in a number of published studies focusing on the detection of VOCs in order to better identify various respiratory pathologies.
While the 400 subject trial will serve as an excellent proof of concept, Zenosense hopes to considerably increase the size of its tests following positive initial results. The company expects the initial trial to take nine months and involve four distinct groups of subjects including healthy smokers, non-smokers and those with diagnosed lung cancer and Chronic Obstructive Pulmonary Disease. The company has already been approved by the ethics committee of the university hospital, meaning that broadening participation to include a host of other public hospitals throughout Spain is possible without the need for further approvals.
If the trials prove successful, Zenosense will be one step closer to taking its revolutionary diagnostic systems to the market. By allowing for superior early detection of lung cancer through non-invasive means, there’s little doubt that the company’s devices would be in a great position to experience tremendous demand. The company predicts that having a way to improve early detection through cost effective screening techniques could offer noticeable improvements to the survivability rates of lung cancer and similar ailments.
VOC detection is a tried and tested method of diagnosing diseases. Just as highly trained dogs have been able to recognize prostate cancer-specific VOCs with up to 98 percent accuracy, Zenosense’s use of a common Electronic Nose technology platform puts it in a great position to improve diagnostic accuracy for a wide range of diseases.
As the company’s trial continues to ramp up, look for Zenosense to make some major waves in the medical and diagnostic industries in the near future. With the possibility of dramatically improving the survivability of some of the world’s most deadly illnesses and servicing multi-billion dollar industries, the sky could be the limit for this detection device development company.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
###
